Stoke Therapeutics develops RNA-based medicines, led by zorevunersen, a candidate in clinical testing for Dravet syndrome, a severe genetic epilepsy. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 21 | JP Morgan | Reinstated | Buy | |
| Aug 4 | Guggenheim | Reiterated | Buy | |
| Aug 4 | Wedbush | Maintained | Buy | |
| Aug 4 | Canaccord Genuity | Maintained | Buy | |
| Jul 13 | Goldman Sachs | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in STOK in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STOK is in one of them and how their past STOK trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered STOK in an article yet. Here's the latest on the wider market.
About Stoke Therapeutics
Stoke Therapeutics is a biopharmaceutical company based in Bedford, Massachusetts, that develops RNA-based medicines. Its TANGO approach uses antisense oligonucleotides to raise levels of specific proteins in diseases caused by a shortage of one working gene copy. Its lead candidate, zorevunersen, is in late stage clinical testing for Dravet syndrome, a severe genetic epilepsy. The company focuses on diseases of the brain and eye and plans to sell its medicines to patients and healthcare providers in the United States, Canada and Mexico.
- Headquarters
- Bedford, MA